Announcements Trials
Browse Landscape

Phase

Phase 2 3

Status

Recruiting 16Active not recruiting 15Completed 8Not yet recruiting 6Terminated 3

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Lymphoid 3Other hematologic neoplasm 2Plasma cell 1Myeloid 1

Conditions

Carcinoma, Non-Small-Cell Lung 46Neoplasms 34Breast Neoplasms 34Melanoma 26Neoplasm Metastasis 24Leukemia, Myeloid, Acute 21Colorectal Neoplasms 20Prostatic Neoplasms 19Lung Neoplasms 17Multiple Myeloma 16Ovarian Neoplasms 14Recurrence 13Myelodysplastic Syndromes 13Lymphoma, Non-Hodgkin 13Squamous Cell Carcinoma of Head and Neck 12Carcinoma, Renal Cell 12Uterine Cervical Neoplasms 11Lymphoma, Large B-Cell, Diffuse 11Carcinoma, Hepatocellular 11Urinary Bladder Neoplasms 10Pancreatic Neoplasms 10Glioblastoma 10Brain Neoplasms 10Stomach Neoplasms 8Head and Neck Neoplasms 8Triple Negative Breast Neoplasms 7Rectal Neoplasms 7Lymphoma, Follicular 7Lymphoma 7Hodgkin Disease 7

Interventions

Cyclophosphamide 2ixazomib 1ibrutinib 1fludarabine 1brexucabtagene autoleucel 1Sirolimus 1Pharmacogenomic Variants 1Mycophenolic Acid 1Cyclosporins 1Cyclosporine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Terminated × Waldenstrom Macroglobulinemia × 90 days × Clear all
NCT03246906 2026-05-14

Comparison of Triple GVHD Prophylaxis Regimens for Nonmyeloablative or Reduced Intensity Conditioning Unrelated Mobilized Blood Cell Transplantation

Fred Hutchinson Cancer Center

Phase 2 Terminated
150 enrolled 18 charts
LymphoidMyeloidOther hematologic neoplasmPlasma cell

Blastic Plasmacytoid Dendritic Cell Neoplasm, Hematologic Diseases, Hodgkin Disease, Waldenstrom Macroglobulinemia, Multiple Myeloma, Myelodysplastic Syndromes, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Prolymphocytic, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Myelodysplastic-Myeloproliferative Diseases

NCT03506373 2026-05-05

Ibrutinib and Ixazomib Citrate in Treating Newly Diagnosed, Relapsed or Refractory Waldenstrom Macroglobulinemia

Mayo Clinic

Phase 2 Terminated
21 enrolled 11 charts
Lymphoid

Waldenstrom Macroglobulinemia

NCT05537766 2026-03-10

ZUMA-25

Gilead Sciences

Phase 2 Terminated
19 enrolled 28 charts
LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Leukemia, Hairy Cell, Waldenstrom Macroglobulinemia, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡